Loeb Benson Hires Sun Huateng as Managing Director and Portfolio Manager
Rejoins the firm as Chief Investment Officer—Non-traditional Strategies and Head of Portfolio Management in Hong Kong OfficeHong Kong – Loeb Benson, a pioneer asset manager focused on the capital markets and financial advice while specializing in maximizing clients’ investment profits, has hired Sun Huateng as a Managing Director and Portfolio Manager.
Mr. Huateng will return to the firm in a new role as Chief Investment Officer—Non-traditional Strategies and Head of Portfolio Management in the Hong Kong office, as well as a member of Loeb Benson’s Investment Committee. He will begin next month and will report to Mr. Richard G. Man-tat, Loeb Benson’s Chairman and Chief Executive Officer.
Mr. Huateng, who was a Senior Portfolio Manager at Loeb Benson, will work closely with Mr. Man-tat on the oversight of several non-traditional investment teams. In addition, he will assume generalist portfolio management responsibilities as part of his new role. In his previous role at Loeb Benson, Mr. Huateng was a member of the Loeb Benson Investment Committee and managed a range of portfolios that included Loeb Benson total return separate accounts.
Said Mr. Man-tat “Sun is a talented, highly experienced investor with broad market expertise and a deep knowledge of Loeb Benson, and his return will further enhance our global investment platform.” Mr. Man-tat continued: “Sun will be able to seamlessly contribute to our investment process and efforts on behalf of Loeb Benson’s clients. We are very pleased that he is returning to Loeb Benson in a senior portfolio management role.”
Said Mr. Huateng “I look forward to return to Loeb Benson and become a member of the firm’s portfolio management team, which is one of the deepest in the investment management industry.”
About Loeb Benson
Loeb Benson is focused on the capital markets and financial advisory needs of the financial services industry while specializing in maximizing clients’ investment profits. With expertise in sales and trading, analytics and asset management, Loeb Benson is uniquely qualified to create value for clients in all market conditions, and we are strategically building on a longstanding commitment to offer a broad range of services. Loeb Benson offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. Our investment solutions, tailored to the unique return and risk objectives of clients draw on a robust body of proprietary research and a collaborative culture that encourages independent thought and healthy debate.
Loeb Benson
Address: Wheelock House, 20 Pedder Street, Hong Kong
public@loeb-benson.com
Kevin Edwards
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Loeb Benson Hires Sun Huateng as Managing Director and Portfolio Manager here
News-ID: 1070797 • Views: …
More Releases from Loeb Benson
Loeb Benson Hires Equity Specialists in Growth and Dividend Strategies to Contin …
Hires Lee Tak-hay, Simon Zhenjiang, Yi Xipeng and Chen Xiuguo in Hong Kong
Hong Kong – Loeb Benson, a pioneer asset manager focused on the capital markets and financial advice while specializing in maximizing clients’ investment profits, has hired Lee Tak-hay, Simon Zhenjiang, Yi Xipeng and Chen Xiuguo to join its Asian equities teams as part of its multi-year effort to deepen and expand its equity solutions for investors.
Mr.…
More Releases for Huateng
Huateng Pharma Supplies PEG Products As Ingredients In mRNA COVID-19 Vaccines
Since the COVID-19 epidemic, Pfizer and Moderna have used mRNA technology in a vaccine to help humans fight COVID-19. While mRNA technology is new to the public, the research has been around since the early 1990s.
What is an mRNA vaccine?
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA (mRNA) to generate an immune response. Such vaccines deliver mRNA molecules into the body's immune cells, where…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
Huateng Pharma Supplies Canagliflozin Intermediates With Commercial Scale Produc …
Canagliflozin is a medication used to treat type 2 diabetes. It is a third-line medication to be tried after metformin, a first-line medication for type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes.
Mechanism action of Canagliflozin
Canagliflozin is a sodium-glucose cotransporter (SGLT2) inhibitor. Glucose filtered in the renal tubular lumen is mainly reabsorbed by SGLT2 expressed in the proximal renal…
Huateng Pharma Supplies Ensitrelvir Intermeidates Against COVID-19
Ensitrelvir (code name S-217622, brand name Xocova), is a new inhibitor of the SARS-CoV-2 major protease (Mpro), also known as 3C-like protease, has been shown to reduce the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters. In cells, low nanomolar to sub-micromolar doses of Ensitrelvir suppress viral growth. In hamsters, oral treatment of Ensitrelvir showed excellent pharmacokinetic qualities and hastened recovery from acute SARS-CoV-2 infection.
Ensitrelvir…
Huateng Pharma Develops Caronic Anhydride & Derivatives As Paxlovid Intermediate …
On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA were published in the New England Journal of Medicine (NEJM).
This NEJM article published viral load data that Paxlovid reduced viral load by 0.868 log10 compared to controls for 5 days of treatment, which equates to a remarkable 7.38-fold reduction in viral load. This pivotal study (NCT04960202) enrolled 2,246 patients with COVID-19, 1,120 received…
Professional Pharmaceutical Intermediates Supplier Huateng Pharma Has Its Own Fa …
Hunan Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide PEG derivatives, biochemical reagents, pharmaceutical intermediates, APIs, Vitamin D Derivatives and targeted anti-tumor drugs.
Today, Huateng Pharma has an R&D base of 5,000 square meters and a smart pharmaceutical industrial park with an investment of RMB 300 million and an industrial park of 34,000 square meters that has been completed and will be put into operation soon.…